Management of Adverse Events – IO/IO and IO/TKI

Opinion
Video

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

  1. Please discuss adverse events associated with IO/IO vs. IO/TKI regimens.
    • What impact do the AE profiles of these combinations have on your selection of systemic therapy for treatment-naïve patients with aRCC?
    • What is the financial impact of managing long-term AEs?
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content